

# **RESEARCH REPORT ON**


# **PIRAMAL PHARMA**

# **LIMITED**



Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.

## COMPANY PROFILE

<b>Piramal Group</b>	
	
Type	Conglomerate
Founded	1984; 39 years ago
Headquarters	Mumbai, Maharashtra, India
Area served	Worldwide
Key people	Ajay Piramal (Chairperson, Managing Director & Chief Executive Officer) Swati Piramal (Vice Chairperson)
Services	Pharmaceutical Healthcare Life sciences Financial services Capital Real estate
Revenue	▲ ₹14,710 crore (US\$1.8 billion) (FY22)
Operating income	▼ ₹6,500 crore (US\$810 million) (FY22)
Net income	▲ ₹1,923.11 crore (US\$240 million) (FY22)




Subsidiaries	Piramal Glass Piramal Enterprises Piramal Pharma Piramal Realty Piramal Steel Piramal Foundation
Website	<a href="http://www.piramal.com">www.piramal.com</a>

## ➤ FUNDAMENTALS


Market Cap	₹18,587Cr	ROE	-1.72%
P/E Ratio(TTM)	0.00	EPS(TTM)	-1.01
P/B Ratio	2.40	Dividend Yield	0.00%
Industry P/E	32.96	Book Value	58.64
Debt to Equity	0.58	Face Value	10

## ➤ SHAREHOLDING




## FINANCIALS


### ➤ REVENUE




### ➤ NET PROFIT




➤ EPS




➤ BVPS



➤ ROE



➤ DEBT TO EQUITY



## TECHNICAL ANALYSIS



**BUY PPL PHARMA MKT 134 TGT 154, 175 SL 114  
(1-3 MONTH)**





## **RATIO ANALYSIS**

ANNUAL	FY 2023	FY 2022
Return on Equity (%)	1.32	6.76
Return on Capital Employed (%)	4.04	8.61
Return on Assets (%)	0.86	4.75
Interest Coverage Ratio (x)	3.79	11.59
Asset Turnover Ratio (x)	0.45	0.48
Price to Earnings (x)	117.65	-
Price to Book (x)	1.55	-
EV/EBITDA (x)	22.18	-
EBITDA Margin (%)	12.73	20.06

**Disclaimer:** This research report is prepared by Shyam Advisory Limited, while making this report we have taken data from available sources and there may be errors in the data shown. We do not guarantee the accuracy of data and recommendation given in this report. Recommendation is for information purpose only. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the Intermediary or provides any assurance of returns to investors.

**"Investment in Securities market is subject to market risks. Read all the related documents carefully before investing."**